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Abstract
Background: Poor compliance with antihypertensive medication is assumed to be an important
reason for unsatisfactory control of blood pressure. Poor compliance is difficult to detect. Each
method of measuring compliance has its own strengths and weaknesses.
The aim of the present study was to compare patient compliance with antihypertensive drugs as
measured by two methods, electronic monitoring versus refill compliance.
Methods: 161 patients with a diagnosis of hypertension for at least a year prior to inclusion, and
inadequate blood pressure control (systolic blood pressure ≥ 160 mmHg and/or diastolic blood
pressure ≥ 95 mmHg) despite the use of antihypertensive drugs, were included. Patients' pharmacy
records from 12 months prior to inclusion were obtained. Refill compliance was calculated as the
number of days for which the pills were prescribed divided by the total number of days in this
period. After inclusion compliance was measured with an electronic monitor that records time and
date of each opening of the pillbox. Agreement between both compliance measures was calculated
using Spearman's correlation coefficient and Cohen's kappa coefficient.
Results: There was very little agreement between the two measures. Whereas refill compliance
showed a large range of values, compliance as measured by electronic monitoring was high in
almost all patients with estimates between 90% and 100%. Cohen's kappa coefficient was 0.005.
Conclusion:  While electronic monitoring is often considered to be the gold standard for
compliance measurements, our results suggest that a short-term electronic monitoring period with
the patient being aware of electronic monitoring is probably insufficient to obtain valid compliance
data. We conclude that there is a strong need for more studies that explore the effect of electronic
monitoring on patient's compliance.
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Background
Lack of compliance with antihypertensive drug regimens
is assumed to be a major cause of failure to achieve ade-
quate blood pressure control [1-3]. It is estimated that that
at least 50% of the patients in a general hypertensive pop-
ulation do not take their antihypertensive medication as
prescribed [4]. Improving compliance with prescribed
drug regimens therefore remains a major challenge to the
physician and it is extremely important to have accurate
measures of compliance.
There is a continuing debate with regard to measurement
of compliance, which is notoriously difficult. An ideal
method to measure compliance should be valid and reli-
able. It should prove ingestion of the medication and give
information about the timing of ingestion. Also the
patient should not be aware of the compliance measure-
ments and not be able to consciously influence the results
[5,6].
At present, electronic monitoring is considered to be the
new "gold standard"[7]. Electronic monitors are normal
pill-bottles with a special cap that contains a microchip
that registers time and date of every time that the bottle is
opened. This method is more sensitive for detecting inad-
equate compliance than other methods, such as self-
reports. However, its costs and other practical issues limit
the use of electronic monitors in routine clinical practice.
Another method to assess compliance is the use of phar-
macy records. Pharmacy refill records provide objective,
unobtrusive and inexpensive estimates of compliance.
Refill records of computerized pharmacy records are used
increasingly as a source of compliance information [8].
Because refill compliance data only give information
about whether or not the medication is obtained by the
patient, it provides an upper bound for medication con-
sumption. It allows identification of those patients that
cannot be compliant simply because they do not obtain
enough medication [8]. It is therefore to be expected that
the actual proportion of patients with poor compliance is
higher. To evaluate the value of using pharmacy records to
identify poor compliers, it would be useful to compare the
use of pharmacy records to determine compliance with a
more sensitive measurement tool, such as electronic mon-
itoring. However, comparisons of refill compliance with
other objective compliance measurement methods within
the same population are scarce.
The aim of the present study was therefore to compare
compliance with antihypertensive drugs assessed by both
refill compliance and electronic monitoring, within a
population of patients with mild hypertension and to
evaluate the agreement between these two compliance
measures.
Methods
Study population
Patients were recruited from general practices in the South
of the Netherlands. Patients were eligible if they met all
following criteria: a) they had a diagnosis of hypertension,
b) they had inadequate blood pressure control despite the
use of antihypertensive medication and c) treatment esca-
lation seemed appropriate. Treatment escalation was
defined as increase in dosage, addition or change of anti-
hypertensive drugs. Hypertension was, according to the
national guideline of the Dutch College of General Practi-
tioners (update 1999) [9], defined as a systolic blood pres-
sure (SBP) ≥ 160 mmHg and/or diastolic blood pressure
(DBP) ≥ 95 mmHg. All patients gave written informed
consent. The Ethical Committee of the Maastricht Univer-
sity approved of the study.
Electronic monitoring
Compliance with antihypertensive medication was meas-
ured by electronic monitoring during two months after
inclusion. Medication was packaged in electronic pill-
boxes (Medication Event Monitoring System (MEMS),
Aardex corp. Geneva). A microprocessor in the bottle cap
registered the date and time of each opening. Each moni-
tor was coded with an identification number that identi-
fied the study participant. At the end of the study, all data
collected by the microprocessor were analyzed using Pow-
erView version 2 software (Aardex corp. Geneva). Each
opening was considered as being a single dose intake. Par-
ticipants were informed that the MEMS monitor recorded
the date and time of each opening of the medication bot-
tle. They were instructed to keep their medication in the
monitoring vial, to use no other source of anti-hyperten-
sive medication and to remove only one dose at a time.
Patients received a MEMS-monitor for each antihyperten-
sive drug they used. Monitoring compliance was
expressed as taking compliance = (total number of doses
taken)/(total number of monitored days) × 100%.
Patients were considered to be compliant if taking compli-
ance was ≥ 85% on each antihypertensive drug they used.
Filled prescriptions
Patients' records from computerized pharmacy systems
were obtained. These records included the names of the
prescribed antihypertensive drug(s), dosage, the quantity
dispensed at each pharmacy fill and the dates of prescrip-
tion fills. Refill compliance was determined from these
pharmacy records during twelve months before the start
of electronic monitoring.
Refill compliance during the interval between two pre-
scription fills was calculated as the number of days for
which the pills were prescribed divided by the total
number of days in this interval. Only those medications
that were filled at least three times during the twelveBMC Health Services Research 2006, 6:8 http://www.biomedcentral.com/1472-6963/6/8
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months were taken into account, so refill compliance
could be calculated for at least two intervals. For each anti-
hypertensive drug average refill compliance was com-
puted by summing the refill compliance in each interval
and dividing the sum by the number of intervals. Patients
were considered to be compliant if average refill compli-
ance was ≥ 85% on each antihypertensive drug they used.
Statistical analysis
First, monitoring compliance (taking compliance) was
plotted against refill compliance in a scatter diagram.
Agreement between the compliance measures on a con-
tinuous scale was calculated using Spearman's correlation
coefficient. Second, patients were classified into two cate-
gories: adequate compliers versus poor compliers. For
both refill compliance and taking compliance patients
were considered to be poor complier if they took less than
85% of any prescribed antihypertensive drug. Agreement
between dichotomized refill and taking compliance was
assessed using overall proportion of agreement, positive
agreement, negative agreement and Cohen's kappa coeffi-
cient, which corrects for chance agreement [10]. In addi-
tional analyses, Cohen's kappa coefficient was
determined using different cut-off points for compliance,
namely 80%, 90% and 95%.
Results
Both monitoring and refill compliance data were availa-
ble for 146 of 161 patients who participated in the study.
Two patients had to be excluded from the analysis since
they did not follow the instructions on the use of the elec-
tronic monitor. Furthermore, the data from two monitors
could not be retrieved due to a technical error. Finally,
from eleven patients' pharmacy records were not available
mainly because the patients moved to other regions. The
baseline characteristics of the patients included in the
analysis are shown in Table 1.
Compliance with antihypertensive medication
Mean taking compliance as measured by electronic mon-
itoring was 96.8 ± 12.1%. Five patients (3.4%) were con-
sidered as poor compliers, because taking compliance of
at least one of their prescribed medications was below
85%. Average compliance in the group of poor compliers
was 59.8 ± 23.9% (p < 0.001).
Mean refill compliance was 108.9 ± 28.3%, indicating
stockpiling of medication by patients. Twenty-seven
patients (18.4%) were identified as poor compliers,
because refill compliance of at least one of their medica-
tions was below 85%. Average refill compliance in these
patients was 86.2 ± 18.6% compared to 114.2 ± 26% in
patients with adequate compliance (p < 0.001). From
those 27 patients considered as poor compliers, 19 were
Comparison of refill compliance versus electronic monitoring  (taking compliance) Figure 1
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Table 1: Demographic and clinical characteristics of included 
patients (n = 146)
Demographic characteristics# (%)
Age
≤ 55 21
56–65 44
66–75 26
≥ 75 8
Gender
Male 48
Female 52
Education
Low 22
Middle 32
High 33
Very high 11
Employed
Yes 31
No 68
Clinical characteristics (Mean (SD))
Years with hypertension 8.5 (8.8)
SBP at inclusion 168.4 (16.3)
DBP at inclusion 95.4 (9.8)
Heart rate 73.2 (12.2)
BMI (kg/m2) 28.6 (5.6)
Nr. of prescribed antihypertensive drugs (%)
14 5
24 1
31 1
> 3 2
Medication regimen (%)
Once daily 84
Twice daily 13
> twice daily 3
# Some categories do not add up to a 100% because data were not 
available for all patientsBMC Health Services Research 2006, 6:8 http://www.biomedcentral.com/1472-6963/6/8
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prescribed more than one antihypertensive drug. In only
four of these patients compliance was not satisfactory
(<85%) for each prescribed antihypertensive drug.
Agreement between electronic monitoring and filled 
prescription
Figure 1 presents a scatter plot for all patients of refill com-
pliance (on the X-axis) versus taking compliance (on the
Y-axis). There was very little agreement between the two
measures and whereas refill compliance showed a large
range of values, compliance as measured by electronic
monitoring was high in almost all patients with estimates
between 90% and 100%. The Spearman's correlation
coefficient was -0.02 (95% CI: [-0.18-0.15]). After classifi-
cation of patients into adequate compliers versus poor
compliers, the agreement between refill compliance and
taking compliance was also poor (Table 2). The overall
proportion of agreement was 0.8. The proportion of neg-
ative agreement, which is the proportion of patients that
are identified as complier by both methods, was 0.89.
However, the proportion of positive agreement, defined
as the proportion of patients that were identified as poor
complier by both methods, was only 0.06. Cohen's kappa
coefficient, which corrects for chance, was 0.005 indicat-
ing a very poor agreement between the two methods to
determine compliance. Also when different cut-off points
for compliance were used, the agreement between the two
methods was poor. Using cut-off points of 80%, 90% and
95%, Cohen's kappa was -0.056, 0.020 and 0.009 respec-
tively (table 3).
Discussion
This study demonstrates that there is a poor agreement
between compliance measured by electronic monitoring
and compliance determined by filled prescription data
within the same population of hypertensive patients. A
remarkable finding is that many patients, who according
to refill compliance data are not compliant with antihy-
pertensive medication, are not identified as such by elec-
tronic monitoring which is considered to be the "gold
standard". With electronic monitoring, less than four per-
cent of the patients could be identified as poor complier.
Using refill data, the percentage of patients with inade-
quate compliance was 18.5 percent. Determination of
compliance based on filled prescriptions was expected to
be a rather insensitive method to measure compliance.
Only a part of the poor compliers can be identified using
this method, because obtaining the medication is no guar-
antee that the patient actually takes them. Therefore refill
compliance is expected to identify the minimum propor-
tion of poor compliers within a population. Despite this
fact, the use of refill data identified a higher percentage of
patients with inadequate compliance than electronic
monitoring. Several explanations may account for these
results.
First, it may be argued that the proportion of poor compli-
ers identified with electronic monitoring would be much
higher when a more stringent measure to define compli-
ance, such as correct dosing, was used. Correct dosing
reflects the percentage of days on which the medication is
taken as prescribed and is therefore much more sensitive
for deviations from the prescribed regimen than taking
compliance data. However, when this measure was
applied to our population only six instead of five patients
were identified as poor complier.
Second, it is possible that electronic monitoring in itself
improves compliance because patients are aware that their
medication behavior is being monitored. This awareness
may have encouraged them to be more compliant than
they used to be before the start of electronic monitoring.
The hypothesis that electronic monitoring in itself
improves compliance, is in agreement with the findings in
other studies, which also point in this direction. First,
most recent studies using electronic monitoring very often
report relatively low proportions of patients with poor
compliance [11-18] in contrast with the general assump-
tion that 40 to 50% of the patients do not take their anti-
hypertensive medication as prescribed. Second, Burnier et
al. [14] demonstrated that a two-month period of moni-
toring of compliance was associated with a significant
improvement of blood pressure, most likely resulting
from increased compliance with antihypertensive drug
therapy. Also Waeber et al. [12] found that three-month
period of monitoring was associated with a significant
improved control of blood pressure.
It can be concluded that the findings in our study stress
the importance of the conditions that need to be met
Table 2: Refill compliance versus electronic monitoring (taking compliance)
Taking compliance
Adequate compliers Poor compliers Total
Refill compliance Adequate compliers 115 4 119
Poor compliers 26 1 27
Total 141 5 146BMC Health Services Research 2006, 6:8 http://www.biomedcentral.com/1472-6963/6/8
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before electronic monitoring can be used to obtain accu-
rate compliance data. First, it seems extremely important
to conceal the purpose of the monitor from the patient to
obtain valid compliance data, but this is really hard to
accomplish in practice. Kruse and Weber [19] found a
compliance of 91% in informed individuals compared to
78% in a group who did not understand the value of the
electronic monitor. Second, studies with a monitoring
period of at least 6 months demonstrate a clear-cut
decrease in compliance over time suggesting that the effect
of awareness of being monitored wanes over time [20-22].
From these studies it can be concluded that it is important
to monitor compliance for at least six months in order to
obtain valid measures of compliance [23].
Some methodological issues deserve further attention.
First, the time periods wherein refill and taking compli-
ance were measured, differed. The short duration of elec-
tronic monitoring (two months) and low refilling
frequency during this time precluded stable estimation of
refill compliance during the monitoring period itself. In
this respect the present study is comparable to the study
performed by Choo et al[24] which found moderate
agreement (r = 0.32) between compliance measured dur-
ing a three month monitoring period and refill compli-
ance in the twelve months before electronic monitoring.
The additional value of the present study is that it gives
information about the proportion of patients with inade-
quate compliance instead of mean values of compliance.
Whereas mean values give the impression that refill com-
pliance is higher than monitoring compliance, propor-
tions indicate that it is the other way around: in
comparison with electronic monitoring, refill compliance
measurements trace more poor compliers.
Second, in the primary analysis a cut-off point for compli-
ance of 85% was used. It is accepted that patients are con-
sidered adherent with the prescribed medication regimen
when they take 80–90% of their medicines [25-27]. How-
ever, historically used cut-off points are in many cases
meaningless as some drugs are much more "forgiving"
than others in term of missed dosing and the timing of
ingestion [28]. The answer to the question "how much
compliance is enough" requires knowledge of the phar-
macokinetic and pharmacodynamic properties, which
vary between antihypertensive drugs and also vary
between individuals. At this stage we do not really know
what level of compliance is necessary for individual anti-
hypertensive medications. To undermine this problem
Cohen's kappa was determined for different cut-off
points. The agreement between both methods was poor,
irrespective of the used cut-off point.
Conclusion
To manage to problem of hypertension there is a need for
accurate methods to measure compliance with medica-
tion. Unrecognized compliance problems may result in
uncontrolled hypertension, unnecessary medication-
switches and even hospitalization. It can be concluded
that a short-term electronic monitoring period with the
patient being aware of electronic monitoring, is probably
insufficient to obtain valid compliance data. Electronic
monitoring may however be a very useful tool to improve
compliance by giving patients insight into their own dos-
ing history. We conclude that there is a strong need for
more studies that explore the effect of electronic monitor-
ing on patient's compliance.
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